StoryCommercial
Tempus reports 2025 revenue of about USD 1.27B, up 83%, and guides to its first positive adjusted EBITDA year
Tempus's 2025 revenue rose about 83%, boosted by the Ambry Genetics purchase, while adjusted EBITDA losses shrank to USD 7.4M. It guided to about USD 1.59B revenue and roughly USD 65M adjusted EBITDA for 2026.
- Net loss of USD 245M, including USD 136.3M of stock compensation.
- Remaining contract value in the data business above USD 1.1B.
- Launched Paige Predict, which reads pathology slides for 123 biomarkers across 16 cancer types.
- Cash of USD 759.7M at year end.